Meeting
2022 ASCO Annual Meeting
A phase II multi-arm study to test the efficacy of oleclumab and durvalumab in specific sarcoma subtypes.
Authors
Neeta Somaiah
The University of Texas MD Anderson Cancer Center, Houston, TX
Neeta Somaiah , J Andrew Andrew Livingston , Vinod Ravi , Heather Y. Lin , Behrang Amini , Luisa Maren Solis , Anthony Paul Conley , Maria Alejandra Zarzour , Joseph Aloysius Ludwig , Ravin Ratan , Wei-Lien Wang , Dejka M. Araujo , Shreyaskumar Patel , Christina Lynn Roland , Alexander J. Lazar , Richard Greg Gorlick , Edwin R. Parra , Cara L. Haymaker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04668300
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS11594)
DOI
10.1200/JCO.2022.40.16_suppl.TPS11594
Abstract #
TPS11594
Poster Bd #
492a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).
First Author: Fabrice Barlesi
Poster
2021 ASCO Annual Meeting
Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).
First Author: Johanna C. Bendell
Poster
2023 ASCO Annual Meeting
NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).
First Author: Florian Guisier
Poster
2022 ASCO Annual Meeting
Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): Primary analysis of the single arm phase II trial SAKK 06/17.
First Author: Richard Cathomas